Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2021

01-05-2021 | SARS-CoV-2 | Original Article

Comparison of various serological assays for novel SARS-COV-2

Authors: María Simón Sacristan, Ana Collazos-Blanco, Maria Isabel Zamora Cintas, Alicia Serrano García, Carmen Ybarra de Villavicencio, María Mateo Maestre

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2021

Login to get access

Abstract

Coronavirus disease-19 (COVID19), the novel respiratory illness caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), is associated with severe morbidity and mortality. The aim of our study was to compare different immunoassays. We evaluated three immunochromatographic test (The StrongStep®SARS-CoV-2 IgG/IgM kit, AllTest COV-19 IgG/IgM kit, and Wondfo® SARS-CoV-2 Antibody) and two chemiluminescence immunoassays (CMIA) (Covid-19 VIRCLIA® IgM+IgA/IgG monotest and the Abbott SARS-CoV-2 IgG assay) in COVID-19 patients. The assays were performed using serum samples of three group patients, i.e., healthy controls, patients with SARS-CoV-2 PCR positive, and patients with SARS-CoV-2 PCR negative clinically diagnosed of COVID-19 infection. The detection percentages of IgG with the StrongStep® SARS-CoV-2 IgG/IgM kit and AllTest COV-19 IgG/IgM kit were similar in both groups (83.3% and 80.6%, respectively in group 2, p = 0.766) and (42.9% and 50.0%, respectively in group 3, p = 0.706). There were some differences on IgM detection between StrongStep® SARS-CoV-2 IgG/IgM kit and AllTest COV-19 IgG/IgM kit (11.1% and 30.6%, respectively in group 2, p = 0.042 and 0.0% and 28.6%, respectively in group 3, p = 0.031). The positive rate of IgG in group 2 is higher compared to group 3 with the two immunoassays tested. We observe the same positive rates of IgG with the two CMIA. Our study shows excellent performance of CMIA compared to immunochromatographic test and confirms its potential use in the diagnosis of the new SARS-CoV-2.
Literature
1.
go back to reference Guan NZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for, Covid (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720CrossRef Guan NZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for, Covid (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720CrossRef
2.
go back to reference Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513CrossRef Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513CrossRef
3.
go back to reference Guo L, Ren L, Yang S, Xiao M, Chang YF, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J (2020) Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 71(15):778–785. Guo L, Ren L, Yang S, Xiao M, Chang YF, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J (2020) Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 71(15):778–785.
4.
go back to reference Pan YG, Fan J, Tang Y, Zhao J, Long X, Guo S, Zhao Z, Liu Y, Hu H, Xue H, Li Y (2020) Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 81(1):28–32 Pan YG, Fan J, Tang Y, Zhao J, Long X, Guo S, Zhao Z, Liu Y, Hu H, Xue H, Li Y (2020) Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 81(1):28–32
5.
go back to reference Li Z, Yang G, Fan J, Tang Y, Zhao J, Long X, Guo S, Zhao Z, Liu Y, Hu H, Xue H, Li Y (2020) Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 92(9):1518–1524 Li Z, Yang G, Fan J, Tang Y, Zhao J, Long X, Guo S, Zhao Z, Liu Y, Hu H, Xue H, Li Y (2020) Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 92(9):1518–1524
6.
go back to reference Zhao YQ, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 71(16):2027–2034 Zhao YQ, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 71(16):2027–2034
7.
go back to reference Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, Carbone V, Vandenberg O, Gulbis B, Wolff F, Rodriguez-Villalobos H (2020) Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol 128:104413CrossRef Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, Carbone V, Vandenberg O, Gulbis B, Wolff F, Rodriguez-Villalobos H (2020) Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol 128:104413CrossRef
8.
go back to reference Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, Terenzi G, Liotti I, Ciotta G, Taddei C, Benucci M, Casprini P, Veneziani F, Fabbri S, Pompetti A, Manfredi M (2020) Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol 9:1671–75 Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, Terenzi G, Liotti I, Ciotta G, Taddei C, Benucci M, Casprini P, Veneziani F, Fabbri S, Pompetti A, Manfredi M (2020) Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol 9:1671–75
9.
go back to reference Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL (2020) Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol 58(8):00941–20 Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL (2020) Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol 58(8):00941–20
10.
go back to reference Jaaskelainen AJ, Kekalainen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, Kurkela S, Lappalainen M (2020) Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Euro Surveill 25(18):2000603 Jaaskelainen AJ, Kekalainen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, Kurkela S, Lappalainen M (2020) Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Euro Surveill 25(18):2000603
11.
go back to reference Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K (2020) The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol 58(8):00797–20 Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K (2020) The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol 58(8):00797–20
12.
go back to reference Zainol Rashid Z, Othman SN, Abdul Samat MN, Ali UK, Wong KK (2020) Diagnostic performance of COVID-19 serology assays. Malays J Pathol 42(1):13–21PubMed Zainol Rashid Z, Othman SN, Abdul Samat MN, Ali UK, Wong KK (2020) Diagnostic performance of COVID-19 serology assays. Malays J Pathol 42(1):13–21PubMed
13.
go back to reference Cai XF, Chen J, Hu JL, Long QX, Deng HJ, Fan K, Liao P, Liu BZ, Wu GC, Chen YK, Li ZJ, Wang K, Zhang XL, Tian WG, Xiang JL, Du HX WJ, Hu Y, Tang N, Lin Y, Ren JH, Huang LY, Wei J, Gan CY, Chen YM, Gao QZ, Chen AM, He CL, Wang DX, Hu P, Zhou FC, Huang AL, Liu P, Wang DQ (2020) A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019 (COVID-19). J Infect Dis 222(2):189–193 Cai XF, Chen J, Hu JL, Long QX, Deng HJ, Fan K, Liao P, Liu BZ, Wu GC, Chen YK, Li ZJ, Wang K, Zhang XL, Tian WG, Xiang JL, Du HX WJ, Hu Y, Tang N, Lin Y, Ren JH, Huang LY, Wei J, Gan CY, Chen YM, Gao QZ, Chen AM, He CL, Wang DX, Hu P, Zhou FC, Huang AL, Liu P, Wang DQ (2020) A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019 (COVID-19). J Infect Dis 222(2):189–193
14.
go back to reference Chia Tan CW, Foo R, Kang AEZ, Peng Y, Sivalingam V, Tiu C, Ong XM, Zhu F, Young BE, Chen MI, Tan YJ, Lye DC, Anderson DE, Wang LF (2020) Serological differentiation between COVID-19 and SARS infections. Emerg Microbes Infect 9(1):1497–1505CrossRef Chia Tan CW, Foo R, Kang AEZ, Peng Y, Sivalingam V, Tiu C, Ong XM, Zhu F, Young BE, Chen MI, Tan YJ, Lye DC, Anderson DE, Wang LF (2020) Serological differentiation between COVID-19 and SARS infections. Emerg Microbes Infect 9(1):1497–1505CrossRef
Metadata
Title
Comparison of various serological assays for novel SARS-COV-2
Authors
María Simón Sacristan
Ana Collazos-Blanco
Maria Isabel Zamora Cintas
Alicia Serrano García
Carmen Ybarra de Villavicencio
María Mateo Maestre
Publication date
01-05-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-04091-4

Other articles of this Issue 5/2021

European Journal of Clinical Microbiology & Infectious Diseases 5/2021 Go to the issue